Bio Innovation Conference | Sally Mossman, Ph.D.
Presented by Maryland Life Sciences, a division of the Maryland Tech Council, the Bio Innovation Conference is driving the future of life sciences in Maryland. This conference provides a forum for professionals from industry, academia and government to discuss trends and insight into Maryland’s burgeoning life sciences industry and topics related to funding, structuring, commercialization and government relations.
Maryland, life sciences, biotechnology, Maryland Tech Council, bio, innovation, conference, Maryland Life Sciences, Bio Innovation Conference, vaccines, gene therapy, networking, Washington DC, DMV, Biohealth, biohealth capital region, sciences, entrepreneurship, entrepreneur, startup, Maryland Life Sciences Bio Innovation Conference, Maryland Tech Council Conference, annual conference
19787
page-template-default,page,page-id-19787,page-child,parent-pageid-16863,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive
 

Sally Mossman, Ph.D.

Sally Mossman, Ph.D.

VP, Head of R&D Center, US, GSK Vaccines

Dr Mossman obtained her PhD in herpes virology from the University of Liverpool, UK. Thereafter she conducted two postdoctoral fellowships in HIV vaccine research in the USA, first at Colorado State University, Fort Collins and then at the University of Washington, Seattle. She spent 8 years within Corixa Corporation, a biotechnology company focusing on developing novel approaches to vaccines, including adjuvants, delivery strategies and proprietary antigen candidates for infectious disease and cancer vaccines. She joined GlaxoSmithKline Vaccines in 2006 and spent 10 years in Rixensart Belgium in the early development of infectious disease vaccines. More recently she relocated to Maryland as part of the founding leadership team for the USA R&D headquarters for GSK Vaccines in Rockville where she was initially heading up the Discovery effort. She is now Head of the Rockville R&D site and oversees a portfolio of vaccine candidates at all stages of development as well as driving key vaccine technologies including mRNA and Adenovirus platforms.